nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—CES2—Mycophenolate mofetil—systemic scleroderma	0.234	0.287	CbGbCtD
Dabigatran etexilate—F2—Captopril—systemic scleroderma	0.19	0.233	CbGbCtD
Dabigatran etexilate—UGT1A9—Mycophenolic acid—systemic scleroderma	0.0883	0.108	CbGbCtD
Dabigatran etexilate—UGT2B7—Mycophenolic acid—systemic scleroderma	0.0835	0.103	CbGbCtD
Dabigatran etexilate—CES1—Mycophenolate mofetil—systemic scleroderma	0.0812	0.0998	CbGbCtD
Dabigatran etexilate—UGT1A9—Mycophenolate mofetil—systemic scleroderma	0.0493	0.0606	CbGbCtD
Dabigatran etexilate—UGT2B7—Mycophenolate mofetil—systemic scleroderma	0.0467	0.0573	CbGbCtD
Dabigatran etexilate—F2—cardial valve—systemic scleroderma	0.0265	0.45	CbGeAlD
Dabigatran etexilate—ABCB1—Lisinopril—systemic scleroderma	0.0136	0.0167	CbGbCtD
Dabigatran etexilate—ABCB1—Captopril—systemic scleroderma	0.0102	0.0125	CbGbCtD
Dabigatran etexilate—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.008	0.00983	CbGbCtD
Dabigatran etexilate—ABCB1—Prednisone—systemic scleroderma	0.00639	0.00786	CbGbCtD
Dabigatran etexilate—F2—artery—systemic scleroderma	0.00398	0.0675	CbGeAlD
Dabigatran etexilate—F2—endothelium—systemic scleroderma	0.00336	0.057	CbGeAlD
Dabigatran etexilate—ABCB1—Methotrexate—systemic scleroderma	0.00321	0.00394	CbGbCtD
Dabigatran etexilate—F2—blood vessel—systemic scleroderma	0.0031	0.0526	CbGeAlD
Dabigatran etexilate—UGT2B15—digestive system—systemic scleroderma	0.0021	0.0355	CbGeAlD
Dabigatran etexilate—CES2—smooth muscle tissue—systemic scleroderma	0.00162	0.0275	CbGeAlD
Dabigatran etexilate—CES2—skin of body—systemic scleroderma	0.0016	0.0271	CbGeAlD
Dabigatran etexilate—F2—connective tissue—systemic scleroderma	0.00159	0.027	CbGeAlD
Dabigatran etexilate—UGT1A9—digestive system—systemic scleroderma	0.00159	0.0269	CbGeAlD
Dabigatran etexilate—CES1—connective tissue—systemic scleroderma	0.00146	0.0247	CbGeAlD
Dabigatran etexilate—UGT2B7—digestive system—systemic scleroderma	0.00128	0.0217	CbGeAlD
Dabigatran etexilate—CES2—digestive system—systemic scleroderma	0.00128	0.0217	CbGeAlD
Dabigatran etexilate—CES2—tendon—systemic scleroderma	0.00122	0.0207	CbGeAlD
Dabigatran etexilate—F2—digestive system—systemic scleroderma	0.00115	0.0195	CbGeAlD
Dabigatran etexilate—NQO2—tendon—systemic scleroderma	0.00109	0.0185	CbGeAlD
Dabigatran etexilate—CES2—lung—systemic scleroderma	0.00107	0.0181	CbGeAlD
Dabigatran etexilate—CES1—digestive system—systemic scleroderma	0.00105	0.0179	CbGeAlD
Dabigatran etexilate—F2—lung—systemic scleroderma	0.00096	0.0163	CbGeAlD
Dabigatran etexilate—NQO2—lung—systemic scleroderma	0.000956	0.0162	CbGeAlD
Dabigatran etexilate—CES1—lung—systemic scleroderma	0.000881	0.0149	CbGeAlD
Dabigatran etexilate—ABCB1—blood vessel—systemic scleroderma	0.000667	0.0113	CbGeAlD
Dabigatran etexilate—ABCB1—digestive system—systemic scleroderma	0.000247	0.00419	CbGeAlD
Dabigatran etexilate—ABCB1—lung—systemic scleroderma	0.000206	0.0035	CbGeAlD
Dabigatran etexilate—Rash—Pentoxifylline—systemic scleroderma	0.000198	0.00156	CcSEcCtD
Dabigatran etexilate—Hypertension—Mycophenolic acid—systemic scleroderma	0.000198	0.00156	CcSEcCtD
Dabigatran etexilate—Dermatitis—Pentoxifylline—systemic scleroderma	0.000197	0.00156	CcSEcCtD
Dabigatran etexilate—Headache—Pentoxifylline—systemic scleroderma	0.000196	0.00155	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000196	0.00154	CcSEcCtD
Dabigatran etexilate—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000195	0.00154	CcSEcCtD
Dabigatran etexilate—Chest pain—Mycophenolic acid—systemic scleroderma	0.000195	0.00154	CcSEcCtD
Dabigatran etexilate—Infection—Leflunomide—systemic scleroderma	0.000194	0.00153	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Captopril—systemic scleroderma	0.000194	0.00153	CcSEcCtD
Dabigatran etexilate—Asthenia—Mometasone—systemic scleroderma	0.000194	0.00153	CcSEcCtD
Dabigatran etexilate—Hypotension—Azathioprine—systemic scleroderma	0.000194	0.00153	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000193	0.00152	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000193	0.00152	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Leflunomide—systemic scleroderma	0.000192	0.00151	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000192	0.00151	CcSEcCtD
Dabigatran etexilate—Pruritus—Mometasone—systemic scleroderma	0.000191	0.00151	CcSEcCtD
Dabigatran etexilate—Anaemia—Lisinopril—systemic scleroderma	0.000191	0.0015	CcSEcCtD
Dabigatran etexilate—Skin disorder—Leflunomide—systemic scleroderma	0.00019	0.0015	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000189	0.00149	CcSEcCtD
Dabigatran etexilate—Angioedema—Lisinopril—systemic scleroderma	0.000188	0.00148	CcSEcCtD
Dabigatran etexilate—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000188	0.00148	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Captopril—systemic scleroderma	0.000188	0.00148	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000187	0.00147	CcSEcCtD
Dabigatran etexilate—Nausea—Pentoxifylline—systemic scleroderma	0.000186	0.00147	CcSEcCtD
Dabigatran etexilate—Infection—Mycophenolic acid—systemic scleroderma	0.000186	0.00146	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Mometasone—systemic scleroderma	0.000185	0.00146	CcSEcCtD
Dabigatran etexilate—Syncope—Lisinopril—systemic scleroderma	0.000185	0.00146	CcSEcCtD
Dabigatran etexilate—Shock—Mycophenolic acid—systemic scleroderma	0.000184	0.00145	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000183	0.00144	CcSEcCtD
Dabigatran etexilate—Hypotension—Leflunomide—systemic scleroderma	0.000183	0.00144	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000183	0.00144	CcSEcCtD
Dabigatran etexilate—Palpitations—Lisinopril—systemic scleroderma	0.000182	0.00144	CcSEcCtD
Dabigatran etexilate—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000181	0.00143	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Lisinopril—systemic scleroderma	0.000181	0.00143	CcSEcCtD
Dabigatran etexilate—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000181	0.00142	CcSEcCtD
Dabigatran etexilate—Cough—Lisinopril—systemic scleroderma	0.00018	0.00142	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000179	0.00141	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000179	0.00141	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000178	0.00141	CcSEcCtD
Dabigatran etexilate—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000178	0.0014	CcSEcCtD
Dabigatran etexilate—Arthralgia—Lisinopril—systemic scleroderma	0.000175	0.00138	CcSEcCtD
Dabigatran etexilate—Chest pain—Lisinopril—systemic scleroderma	0.000175	0.00138	CcSEcCtD
Dabigatran etexilate—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000175	0.00138	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Leflunomide—systemic scleroderma	0.000175	0.00138	CcSEcCtD
Dabigatran etexilate—Hypotension—Mycophenolic acid—systemic scleroderma	0.000175	0.00138	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000174	0.00137	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Leflunomide—systemic scleroderma	0.000172	0.00136	CcSEcCtD
Dabigatran etexilate—Vomiting—Mometasone—systemic scleroderma	0.000172	0.00135	CcSEcCtD
Dabigatran etexilate—Rash—Mometasone—systemic scleroderma	0.000171	0.00134	CcSEcCtD
Dabigatran etexilate—Asthenia—Captopril—systemic scleroderma	0.00017	0.00134	CcSEcCtD
Dabigatran etexilate—Dermatitis—Mometasone—systemic scleroderma	0.00017	0.00134	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00017	0.00134	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Methotrexate—systemic scleroderma	0.00017	0.00134	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00017	0.00134	CcSEcCtD
Dabigatran etexilate—Headache—Mometasone—systemic scleroderma	0.000169	0.00133	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000169	0.00133	CcSEcCtD
Dabigatran etexilate—Fatigue—Leflunomide—systemic scleroderma	0.000169	0.00133	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000168	0.00133	CcSEcCtD
Dabigatran etexilate—Pruritus—Captopril—systemic scleroderma	0.000168	0.00132	CcSEcCtD
Dabigatran etexilate—Constipation—Leflunomide—systemic scleroderma	0.000167	0.00132	CcSEcCtD
Dabigatran etexilate—Infection—Lisinopril—systemic scleroderma	0.000167	0.00132	CcSEcCtD
Dabigatran etexilate—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000167	0.00132	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000167	0.00131	CcSEcCtD
Dabigatran etexilate—Shock—Lisinopril—systemic scleroderma	0.000165	0.0013	CcSEcCtD
Dabigatran etexilate—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000165	0.0013	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000165	0.0013	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000164	0.0013	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Azathioprine—systemic scleroderma	0.000164	0.00129	CcSEcCtD
Dabigatran etexilate—Skin disorder—Lisinopril—systemic scleroderma	0.000163	0.00129	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Captopril—systemic scleroderma	0.000163	0.00128	CcSEcCtD
Dabigatran etexilate—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000162	0.00128	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000161	0.00127	CcSEcCtD
Dabigatran etexilate—Fatigue—Mycophenolic acid—systemic scleroderma	0.000161	0.00127	CcSEcCtD
Dabigatran etexilate—Nausea—Mometasone—systemic scleroderma	0.000161	0.00127	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00016	0.00126	CcSEcCtD
Dabigatran etexilate—Constipation—Mycophenolic acid—systemic scleroderma	0.00016	0.00126	CcSEcCtD
Dabigatran etexilate—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00016	0.00126	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000159	0.00125	CcSEcCtD
Dabigatran etexilate—Cough—Mycophenolate mofetil—systemic scleroderma	0.000158	0.00124	CcSEcCtD
Dabigatran etexilate—Hypotension—Lisinopril—systemic scleroderma	0.000157	0.00124	CcSEcCtD
Dabigatran etexilate—Dizziness—Captopril—systemic scleroderma	0.000157	0.00124	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000157	0.00124	CcSEcCtD
Dabigatran etexilate—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000156	0.00123	CcSEcCtD
Dabigatran etexilate—Urticaria—Leflunomide—systemic scleroderma	0.000156	0.00123	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Leflunomide—systemic scleroderma	0.000155	0.00122	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000154	0.00122	CcSEcCtD
Dabigatran etexilate—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000154	0.00121	CcSEcCtD
Dabigatran etexilate—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000154	0.00121	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Prednisone—systemic scleroderma	0.000154	0.00121	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000153	0.00121	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Azathioprine—systemic scleroderma	0.000153	0.0012	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000153	0.0012	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000153	0.0012	CcSEcCtD
Dabigatran etexilate—Vomiting—Captopril—systemic scleroderma	0.000151	0.00119	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Lisinopril—systemic scleroderma	0.00015	0.00118	CcSEcCtD
Dabigatran etexilate—Rash—Captopril—systemic scleroderma	0.00015	0.00118	CcSEcCtD
Dabigatran etexilate—Dermatitis—Captopril—systemic scleroderma	0.00015	0.00118	CcSEcCtD
Dabigatran etexilate—Headache—Captopril—systemic scleroderma	0.000149	0.00117	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Lisinopril—systemic scleroderma	0.000148	0.00117	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000148	0.00116	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000147	0.00116	CcSEcCtD
Dabigatran etexilate—Infection—Mycophenolate mofetil—systemic scleroderma	0.000146	0.00115	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000145	0.00114	CcSEcCtD
Dabigatran etexilate—Fatigue—Lisinopril—systemic scleroderma	0.000145	0.00114	CcSEcCtD
Dabigatran etexilate—Shock—Mycophenolate mofetil—systemic scleroderma	0.000145	0.00114	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000145	0.00114	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000144	0.00114	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Leflunomide—systemic scleroderma	0.000144	0.00114	CcSEcCtD
Dabigatran etexilate—Constipation—Lisinopril—systemic scleroderma	0.000144	0.00113	CcSEcCtD
Dabigatran etexilate—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00113	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Azathioprine—systemic scleroderma	0.000142	0.00112	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Prednisone—systemic scleroderma	0.000141	0.00111	CcSEcCtD
Dabigatran etexilate—Nausea—Captopril—systemic scleroderma	0.000141	0.00111	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000141	0.00111	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Prednisone—systemic scleroderma	0.000141	0.00111	CcSEcCtD
Dabigatran etexilate—Asthenia—Leflunomide—systemic scleroderma	0.00014	0.00111	CcSEcCtD
Dabigatran etexilate—Pruritus—Leflunomide—systemic scleroderma	0.000139	0.00109	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Prednisone—systemic scleroderma	0.000138	0.00109	CcSEcCtD
Dabigatran etexilate—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000138	0.00109	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000138	0.00108	CcSEcCtD
Dabigatran etexilate—Dizziness—Azathioprine—systemic scleroderma	0.000137	0.00108	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000136	0.00108	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000134	0.00106	CcSEcCtD
Dabigatran etexilate—Asthenia—Mycophenolic acid—systemic scleroderma	0.000134	0.00106	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Leflunomide—systemic scleroderma	0.000134	0.00106	CcSEcCtD
Dabigatran etexilate—Urticaria—Lisinopril—systemic scleroderma	0.000134	0.00105	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Lisinopril—systemic scleroderma	0.000133	0.00105	CcSEcCtD
Dabigatran etexilate—Pruritus—Mycophenolic acid—systemic scleroderma	0.000132	0.00104	CcSEcCtD
Dabigatran etexilate—Vomiting—Azathioprine—systemic scleroderma	0.000132	0.00104	CcSEcCtD
Dabigatran etexilate—Pneumonia—Methotrexate—systemic scleroderma	0.000132	0.00104	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000131	0.00104	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Methotrexate—systemic scleroderma	0.000131	0.00103	CcSEcCtD
Dabigatran etexilate—Infestation—Methotrexate—systemic scleroderma	0.000131	0.00103	CcSEcCtD
Dabigatran etexilate—Rash—Azathioprine—systemic scleroderma	0.000131	0.00103	CcSEcCtD
Dabigatran etexilate—Dermatitis—Azathioprine—systemic scleroderma	0.000131	0.00103	CcSEcCtD
Dabigatran etexilate—Headache—Azathioprine—systemic scleroderma	0.00013	0.00102	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00013	0.00102	CcSEcCtD
Dabigatran etexilate—Dizziness—Leflunomide—systemic scleroderma	0.000129	0.00102	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000128	0.00101	CcSEcCtD
Dabigatran etexilate—Angiopathy—Prednisone—systemic scleroderma	0.000128	0.00101	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000127	0.001	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Prednisone—systemic scleroderma	0.000127	0.001	CcSEcCtD
Dabigatran etexilate—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000126	0.000993	CcSEcCtD
Dabigatran etexilate—Haematuria—Methotrexate—systemic scleroderma	0.000125	0.000984	CcSEcCtD
Dabigatran etexilate—Vomiting—Leflunomide—systemic scleroderma	0.000124	0.000981	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Lisinopril—systemic scleroderma	0.000124	0.000977	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000124	0.000976	CcSEcCtD
Dabigatran etexilate—Dizziness—Mycophenolic acid—systemic scleroderma	0.000123	0.000973	CcSEcCtD
Dabigatran etexilate—Epistaxis—Methotrexate—systemic scleroderma	0.000123	0.000973	CcSEcCtD
Dabigatran etexilate—Rash—Leflunomide—systemic scleroderma	0.000123	0.000973	CcSEcCtD
Dabigatran etexilate—Dermatitis—Leflunomide—systemic scleroderma	0.000123	0.000972	CcSEcCtD
Dabigatran etexilate—Nausea—Azathioprine—systemic scleroderma	0.000123	0.00097	CcSEcCtD
Dabigatran etexilate—Headache—Leflunomide—systemic scleroderma	0.000123	0.000966	CcSEcCtD
Dabigatran etexilate—Malnutrition—Prednisone—systemic scleroderma	0.000122	0.000965	CcSEcCtD
Dabigatran etexilate—Asthenia—Lisinopril—systemic scleroderma	0.000121	0.000951	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000121	0.00095	CcSEcCtD
Dabigatran etexilate—Pruritus—Lisinopril—systemic scleroderma	0.000119	0.000938	CcSEcCtD
Dabigatran etexilate—Vomiting—Mycophenolic acid—systemic scleroderma	0.000119	0.000936	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Methotrexate—systemic scleroderma	0.000118	0.000931	CcSEcCtD
Dabigatran etexilate—Rash—Mycophenolic acid—systemic scleroderma	0.000118	0.000928	CcSEcCtD
Dabigatran etexilate—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000118	0.000927	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Methotrexate—systemic scleroderma	0.000118	0.000926	CcSEcCtD
Dabigatran etexilate—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000923	CcSEcCtD
Dabigatran etexilate—Headache—Mycophenolic acid—systemic scleroderma	0.000117	0.000922	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000918	CcSEcCtD
Dabigatran etexilate—Nausea—Leflunomide—systemic scleroderma	0.000116	0.000916	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000116	0.000914	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Methotrexate—systemic scleroderma	0.000115	0.000908	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Lisinopril—systemic scleroderma	0.000115	0.000907	CcSEcCtD
Dabigatran etexilate—Anaemia—Prednisone—systemic scleroderma	0.000113	0.000891	CcSEcCtD
Dabigatran etexilate—Angioedema—Prednisone—systemic scleroderma	0.000112	0.000881	CcSEcCtD
Dabigatran etexilate—Dizziness—Lisinopril—systemic scleroderma	0.000111	0.000876	CcSEcCtD
Dabigatran etexilate—Nausea—Mycophenolic acid—systemic scleroderma	0.000111	0.000874	CcSEcCtD
Dabigatran etexilate—Syncope—Prednisone—systemic scleroderma	0.00011	0.000865	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Methotrexate—systemic scleroderma	0.000109	0.000859	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000856	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Prednisone—systemic scleroderma	0.000108	0.000848	CcSEcCtD
Dabigatran etexilate—Vomiting—Lisinopril—systemic scleroderma	0.000107	0.000843	CcSEcCtD
Dabigatran etexilate—Angiopathy—Methotrexate—systemic scleroderma	0.000107	0.00084	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Methotrexate—systemic scleroderma	0.000106	0.000836	CcSEcCtD
Dabigatran etexilate—Rash—Lisinopril—systemic scleroderma	0.000106	0.000836	CcSEcCtD
Dabigatran etexilate—Dermatitis—Lisinopril—systemic scleroderma	0.000106	0.000835	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000106	0.000835	CcSEcCtD
Dabigatran etexilate—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000833	CcSEcCtD
Dabigatran etexilate—Hypertension—Prednisone—systemic scleroderma	0.000106	0.000833	CcSEcCtD
Dabigatran etexilate—Headache—Lisinopril—systemic scleroderma	0.000105	0.00083	CcSEcCtD
Dabigatran etexilate—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000822	CcSEcCtD
Dabigatran etexilate—Arthralgia—Prednisone—systemic scleroderma	0.000104	0.000821	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000103	0.000816	CcSEcCtD
Dabigatran etexilate—Malnutrition—Methotrexate—systemic scleroderma	0.000102	0.000806	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000795	CcSEcCtD
Dabigatran etexilate—Nausea—Lisinopril—systemic scleroderma	9.99e-05	0.000787	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Prednisone—systemic scleroderma	9.99e-05	0.000787	CcSEcCtD
Dabigatran etexilate—Infection—Prednisone—systemic scleroderma	9.93e-05	0.000782	CcSEcCtD
Dabigatran etexilate—Back pain—Methotrexate—systemic scleroderma	9.9e-05	0.00078	CcSEcCtD
Dabigatran etexilate—Shock—Prednisone—systemic scleroderma	9.83e-05	0.000774	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Prednisone—systemic scleroderma	9.8e-05	0.000772	CcSEcCtD
Dabigatran etexilate—Dizziness—Mycophenolate mofetil—systemic scleroderma	9.75e-05	0.000768	CcSEcCtD
Dabigatran etexilate—Skin disorder—Prednisone—systemic scleroderma	9.7e-05	0.000765	CcSEcCtD
Dabigatran etexilate—Anaemia—Methotrexate—systemic scleroderma	9.46e-05	0.000745	CcSEcCtD
Dabigatran etexilate—Vomiting—Mycophenolate mofetil—systemic scleroderma	9.37e-05	0.000738	CcSEcCtD
Dabigatran etexilate—Rash—Mycophenolate mofetil—systemic scleroderma	9.29e-05	0.000732	CcSEcCtD
Dabigatran etexilate—Dermatitis—Mycophenolate mofetil—systemic scleroderma	9.28e-05	0.000732	CcSEcCtD
Dabigatran etexilate—Headache—Mycophenolate mofetil—systemic scleroderma	9.23e-05	0.000728	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Prednisone—systemic scleroderma	9.1e-05	0.000717	CcSEcCtD
Dabigatran etexilate—Cough—Methotrexate—systemic scleroderma	8.93e-05	0.000703	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Prednisone—systemic scleroderma	8.79e-05	0.000693	CcSEcCtD
Dabigatran etexilate—Nausea—Mycophenolate mofetil—systemic scleroderma	8.75e-05	0.00069	CcSEcCtD
Dabigatran etexilate—Chest pain—Methotrexate—systemic scleroderma	8.71e-05	0.000686	CcSEcCtD
Dabigatran etexilate—Arthralgia—Methotrexate—systemic scleroderma	8.71e-05	0.000686	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	8.65e-05	0.000682	CcSEcCtD
Dabigatran etexilate—Fatigue—Prednisone—systemic scleroderma	8.61e-05	0.000679	CcSEcCtD
Dabigatran etexilate—Constipation—Prednisone—systemic scleroderma	8.54e-05	0.000673	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Methotrexate—systemic scleroderma	8.35e-05	0.000658	CcSEcCtD
Dabigatran etexilate—Infection—Methotrexate—systemic scleroderma	8.29e-05	0.000654	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Methotrexate—systemic scleroderma	8.19e-05	0.000645	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Methotrexate—systemic scleroderma	8.17e-05	0.000644	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Prednisone—systemic scleroderma	8.17e-05	0.000644	CcSEcCtD
Dabigatran etexilate—Skin disorder—Methotrexate—systemic scleroderma	8.11e-05	0.000639	CcSEcCtD
Dabigatran etexilate—Urticaria—Prednisone—systemic scleroderma	7.94e-05	0.000625	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Prednisone—systemic scleroderma	7.9e-05	0.000622	CcSEcCtD
Dabigatran etexilate—Hypotension—Methotrexate—systemic scleroderma	7.8e-05	0.000615	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	7.61e-05	0.000599	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Methotrexate—systemic scleroderma	7.44e-05	0.000587	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Prednisone—systemic scleroderma	7.36e-05	0.00058	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Methotrexate—systemic scleroderma	7.35e-05	0.000579	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Methotrexate—systemic scleroderma	7.21e-05	0.000568	CcSEcCtD
Dabigatran etexilate—Fatigue—Methotrexate—systemic scleroderma	7.2e-05	0.000567	CcSEcCtD
Dabigatran etexilate—Asthenia—Prednisone—systemic scleroderma	7.17e-05	0.000565	CcSEcCtD
Dabigatran etexilate—Pruritus—Prednisone—systemic scleroderma	7.07e-05	0.000557	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Prednisone—systemic scleroderma	6.84e-05	0.000539	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Methotrexate—systemic scleroderma	6.83e-05	0.000538	CcSEcCtD
Dabigatran etexilate—Urticaria—Methotrexate—systemic scleroderma	6.63e-05	0.000523	CcSEcCtD
Dabigatran etexilate—Dizziness—Prednisone—systemic scleroderma	6.61e-05	0.000521	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Methotrexate—systemic scleroderma	6.6e-05	0.00052	CcSEcCtD
Dabigatran etexilate—Vomiting—Prednisone—systemic scleroderma	6.35e-05	0.000501	CcSEcCtD
Dabigatran etexilate—Rash—Prednisone—systemic scleroderma	6.3e-05	0.000496	CcSEcCtD
Dabigatran etexilate—Dermatitis—Prednisone—systemic scleroderma	6.29e-05	0.000496	CcSEcCtD
Dabigatran etexilate—Headache—Prednisone—systemic scleroderma	6.26e-05	0.000493	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Methotrexate—systemic scleroderma	6.15e-05	0.000485	CcSEcCtD
Dabigatran etexilate—Asthenia—Methotrexate—systemic scleroderma	5.99e-05	0.000472	CcSEcCtD
Dabigatran etexilate—Nausea—Prednisone—systemic scleroderma	5.93e-05	0.000468	CcSEcCtD
Dabigatran etexilate—Pruritus—Methotrexate—systemic scleroderma	5.91e-05	0.000465	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Methotrexate—systemic scleroderma	5.71e-05	0.00045	CcSEcCtD
Dabigatran etexilate—Dizziness—Methotrexate—systemic scleroderma	5.52e-05	0.000435	CcSEcCtD
Dabigatran etexilate—Vomiting—Methotrexate—systemic scleroderma	5.31e-05	0.000418	CcSEcCtD
Dabigatran etexilate—Rash—Methotrexate—systemic scleroderma	5.26e-05	0.000415	CcSEcCtD
Dabigatran etexilate—Dermatitis—Methotrexate—systemic scleroderma	5.26e-05	0.000414	CcSEcCtD
Dabigatran etexilate—Headache—Methotrexate—systemic scleroderma	5.23e-05	0.000412	CcSEcCtD
Dabigatran etexilate—Nausea—Methotrexate—systemic scleroderma	4.96e-05	0.000391	CcSEcCtD
